This is the authors' abstract. We don't add key points for this paper.
The tight-skin (TSK/+) mouse, a genetic model for human systemic sclerosis (SSc), develops cutaneous fibrosis and autoantibodies against SSc-specific target autoantigens.Although molecular mechanisms explaining the development of fibrosis and autoimmunity in SSc patients or TSK/+ mice remain unknown, we recently demonstrated that SSc patients overexpress CD19, an important regulatory molecule expressed by B lymphocytes.B cells from CD19-deficient mice are hyporesponsive to transmembrane signals, while B cells overexpressing CD19 are hyperresponsive and generate autoantibodies.In this study, TSK/+ B cells also exhibited a hyperresponsive phenotype with decreased surface IgM expression, enhanced serum Ig production, and spontaneous autoantibody production.Moreover, CD19 tyrosine phosphorylation was constitutively augmented in TSK/+ B cells.CD19-mediated [Ca 2+ ] i responses, Vav phosphorylation, and Lyn kinase activity were similarly enhanced.Studies of TSK/+ mice deficient in CD19 expression demonstrated that CD19 deficiency significantly decreased skin fibrosis in TSK/+ mice.Additionally, CD19 loss in TSK/+ mice upregulated surface IgM expression and completely abrogated hyper-γ-globulinemia and autoantibody production.CD19 deficiency also inhibited IL-6 production by TSK/+ B cells.Thus, chronic B cell activation resulting from augmented CD19 signaling in TSK/+ mice leads to skin sclerosis possibly through IL-6 overproduction as well as autoimmunity.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: